Background. The frequency of protective antiviral memory B cells after hepatitis B virus (HBV) vaccination is unknown.
The long-term humoral immunity elicited by most vaccines is due to long-lived plasma and memory B cells [1] . Plasma cells are terminally differentiated and have been proposed to be either short-lived or long-lived, with short-lived plasma cells able to produce antibody shortly after antigen exposure and long-lived plasma cells able to provide long-term continuous secretion of antibody [2, 3] . In contrast, memory B cells proliferate and differentiate into antibody-secreting cells after reencountering antigen. It is thought that memory B cells may differentiate into long-lived plasma cells, which subsequently help maintain serum antibody levels [3, 4] . Overall, the role of memory B cells appears to be critical for long-term production of antibody.
Serum antibody responses to vaccines have been shown to persist for Ͼ60 years [5] . However, although some vaccines are able to elicit responses by long-lived memory B cells that support long-term antibody production via differentiation into plasma cells, this stability of persistent antibody titers is not universal [6] . In particular, serum titers of antibody against hepatitis B virus (HBV) surface antigen (HBsAg) have been shown to decrease below the established minimum protective level of 10 mIU/mL within a few years after vaccination [7] . However, it is now thought that protection from HBV exposure is lifelong regardless of antibody titer, because of T cell responses [8] or very low antibody titers [9] .
Direct ex vivo enumeration of virus-specific T cells has yielded very important insights into antiviral T cell responses [10] . We reasoned that evaluation of the antiviral B cell compartment in a similar manner might subsequently yield an equivalent appreciation of this critical but underinvestigated population. HBV is a particularly appropriate model for such study, because antibodies play a major role in vaccine-induced protection and because we can compare HBV-vaccinated individuals with unvaccinated individuals.
Subjects, materials, and methods. Healthy individuals who were or were not vaccinated against HBV were selected from consenting volunteers and the National Blood Service in the United Kingdom. Subjects were considered unvaccinated if they had an anti-HBsAg titer of Ͻ10 IU/L and no previous vaccination or HBV exposure. Peripheral blood mononuclear cells (PBMCs) were obtained from subjects by centrifugation of heparinized blood over Lymphoprep (Nycomed). PBMCs were resuspended in RPMI 1640 containing 10% human AB serum (First Link), 100 g/mL of streptomycin, 100 U/mL of penicillin, and 2 mmol/L of glutamine (RPMI-10). Plasma was obtained from heparinized blood by centrifugation of the blood at 16,100 g for 10 min in a microcentrifuge and was stored at Ϫ20°C. Determination of anti-HBsAg titers from the plasma samples was performed using automated enzyme-linked immunosorbent spot (ELISPOT) analysis (AxSYM HBsAg [Abbott Laboratories]) in the Department of Virology at John Radcliffe Hospital (Oxford, United Kingdom). All samples were obtained with approval of the local ethics research committee.
HBsAg-specific B cells were enriched using a 2-step, highgradient, magnetic cell-sorting procedure described elsewhere [11] . Briefly, CD19 ϩ B cells were enriched from Ͼ50 ϫ 10 6 PBMCs, using CD19 multisort microbeads (Miltenyi Biotec) and MACS (Miltenyi Biotec). After release of the magnetic microbeads, the preenriched CD19 ϩ B cells were labeled initially with HBsAg-conjugated microbeads (Miltenyi Biotec) at 4°C for 15 min, after which HBsAg-conjugated PE (Miltenyi Biotec), anti-CD27-FITC, anti-CD14-PerCP, VIAprobe, and anti-CD19-APC (BD Biosciences) were added. The magnetically labeled cells were then enriched using MACS. A 50-L preenrichment sample was taken before the HBsAg-conjugated microbead magnetic separation and was used to calculate the frequency of HBsAg-specific cells in the CD19 ϩ population, according to the following formula: the absolute number of HBsAg ϩ cells in the postenrichment sample divided by the total number of CD19 ϩ B cells in the preenrichment sample, multiplied by 9. The factor of 9 was used because of the postenrichment of HBsAg ϩ cells from the 450-L sample that remained after use of 50 L to calculate the total number of CD19 . Two ELISPOT analyses per patient were performed on the above antigens. An ex vivo ELISPOT analysis was performed to determine the frequency of plasma B cells, and a cultured ELISPOT analysis was performed to determine the frequency of memory B cells. Coated plates were washed 3 times with PBS, and 2 ϫ 10 5 cells per well were added. Plates were incubated for 20 -24 h at 37°C and washed 5 times with PBS. Next, 100 L IgG-alkaline phosphatase conjugate diluted in RPMI-10 (dilution, 1:5000 [Calbiochem]) was added, and the plates were incubated at room temperature for 4 h. The plate was washed 3 times with PBS and then 3 times with water before the spots were developed using an AP conjugate substrate kit (Bio-Rad).
Results. Sixteen vaccinated and 9 unvaccinated healthy individuals were tested for the presence of HBsAg-specific memory B cells in the PBMC population, using a direct ex vivo staining technique. The CD19 ϩ HBsAg ϩ B cell population was magnetically enriched from freshly isolated PBMCs and stained with antibodies (figure 1). CD19 was added as a B cell marker, IgG or CD27 was added as a marker for the memory B cell population, and CD14 and VIAprobe were added to exclude monocyte/macrophage and dead cell populations, respectively.
The To compare these findings with those of an alternative assay, B cell ELISPOT analyses were performed. Because of the extremely low frequency of HBsAg-specific memory B cells detected during fluorescence-activated cell sorting (FACS) analysis, it was perhaps unsurprising that direct ex vivo ELISPOT analysis of the HBsAg-specific antibody secreting cells (ASCs), which should detect both short-term and long-term plasma cells, showed no responses (data not shown). However, when PBMCs were cultured for 5 days to allow the existing memory B cell population to proliferate and differentiate into plasma cells, a detectable response was found in 7 (43.75%) of 16 vaccinated individuals, compared with 1 (11.11%) of 9 unvaccinated individuals (P ϭ .1415, by the Mann-Whitney unpaired t test) (figure 2E). The detection of positive test results among individuals in the unvaccinated group may have been due to an irregular nonspecific expansion of naive precursor B cells from the relatively small population of stimulated PBMCs. The FACS analysis of HBsAg-specific B cells showed no differences in frequency between this single individual and the other 8 individuals from the unvaccinated group. No correlation was seen between the relative frequencies of HBsAg-specific B cells detected by FACS analysis and ELISPOT analysis among 11 HBV-vaccinated individuals for whom data were available (P ϭ .314).
Discussion. Unlike the detection of CD4 ϩ and CD8 ϩ T cells, detection of either memory or plasma B cells is difficult, because of the lack of methods or reagents that allow reliable discrimination of antigen-specific cells. Therefore, the key relationship between the levels of serum antibody and the presence of circulating B cells has been difficult to address. Previous techniques for analyzing the frequency of antiviral protective memory B cells have involved longterm culture followed by ELISA [4] or short-term culture followed by ELISPOT analysis [12] . However, culture of these cell populations alters the frequency, and direct ex vivo detection is vital to allow accurate evaluation of relationships. We adapted the 2-step immunomagnetic enrichment method previously used for detec-tion of antigen-specific B cells to allow, for the first time, accurate enumeration of the ex vivo frequency of a virus-specific memory B cell population [11] . These responses are possibly quite longlasting, considering that the half-life of serum antibody titers to viral antigens has been estimated to vary between 11 and 11,522 years [13] . Hence, the longevity of any memory B cell population is an important issue to address in future studies.
Our results show that we were able to detect a population of memory B cells that were specific for HBsAg and also that no correlation existed between the serum antibody titers and the antigen- specific memory B cells in the HBsAg-vaccinated individuals. This contrasts with findings of a study that used a long-term culture method involving the transformation of B cells with Epstein-Barr virus followed by performance of a limiting-dilution assay [14] . As mentioned, in vitro manipulation of B cells will influence the eventual frequency of the antigen-specific B cells, which is the most plausible explanation for the differing results. Another important difference is that the previous study analyzed the B cell frequency 2 weeks after the third dose of HBV vaccine was administered, a time during the postvaccination phase at which there may be an accurate correlation between antigen-specific B cells and serum titers. However, in relation to both studies, it is interesting to note that a recent study has shown that no significant correlation existed between peripheral memory B cell counts and serum antibody levels for 5 of 8 viral antigens assessed [13] . Furthermore, these 5 viral antigens were generally exposed to individuals on a repeated basis by either vaccination or virus exposure.
ELISPOT for the detection of plasma cells did not detect any cells ex vivo for any of the vaccinated individuals. This finding is likely due to the localization of plasma cells within the bone marrow and secondary lymphoid organs. Of interest, the positive responses observed after short-term stimulation were in individuals with higher serum antibody titers, indicating that high titers may correlate with antibody-secreting cells circulating in the peripheral blood. Ex vivo responses to HBsAg have been detected before by ELISPOT analysis, but these were only transiently present after a booster dose and were not detectable after 9 days [15] . In our hands, the immunomagnetic technique pro- vided greater sensitivity for analysis of long-term responses of memory cells.
Overall, we have shown that a novel method can reveal the magnitude of the protective B cell response following immunization with an HBV vaccine. Unlike the data that emerged when such ex vivo techniques were used to measure T cell responses, which revealed unexpectedly large populations, and in contrast to findings obtained with in vitro techniques [10] , we found very small populations on which protective immunity ultimately depends. The long-term protection against HBV infection provided by vaccination is independent of sustained antibody titers [9] , but the proposed protective B cell memory can now be visualized. The method can be applied to a range of antiviral protective responses and could be used to evaluate not only the frequency but the surface phenotype, gene expression profile, and other aspects of the biological characteristics of such key memory populations ex vivo. In this study, we used CD27 cell expression to define the memory B cell population, and equivalent data may be obtained using surface IgG as a marker (data not shown). By use of polychromatic flow cytometry, it may be possible to add additional markers, while maintaining tight positive inclusion and negative exclusion gates. Defining the life span and turnover of such cell populations in vivo remains an important goal in vaccinology, and methods of direct evaluation will be extremely useful in the creation of these definitions.
